Diagnosis, management and outcomes of adults hospitalized with influenza

Antiviral Therapy

Volumn 17, Issue 1 PART B, 2012, Pages 143-157

  Lee, Nelson ^a   Ison, Michael G ^b  

^a Faculty of Medicine   (Hong Kong)

^b NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMANTADINE; ANTIVIRUS AGENT; INFLUENZA VACCINE; LANINAMIVIR; OSELTAMIVIR; PERAMIVIR; RIBAVIRIN; RIMANTADINE; SIALIDASE INHIBITOR; VIRUS RNA; ZANAMIVIR;

2009 H1N1 INFLUENZA; ADULT; ADULT RESPIRATORY DISTRESS SYNDROME; AGE; ANTIGEN DETECTION; ANTIVIRAL RESISTANCE; BACTERIAL PNEUMONIA; BACTERIAL SUPERINFECTION; CARDIOVASCULAR DISEASE; CEREBROVASCULAR DISEASE; CLINICAL FEATURE; CONTROLLED CLINICAL TRIAL (TOPIC); DIAGNOSTIC PROCEDURE; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG ADMINISTRATION ROUTE; DRUG DOSE COMPARISON; DRUG DOSE REGIMEN; DRUG EFFICACY; EARLY INTERVENTION; ENZYME IMMUNOASSAY; FEVER; HAND WASHING; HOSPITAL INFECTION; HOSPITALIZATION; HUMAN; IMMUNOCOMPROMISED PATIENT; IMMUNOFLUORESCENCE MICROSCOPY; INFECTION RISK; INFLUENZA A (H5N1); LUNG DISEASE; MEDICAL DECISION MAKING; MORTALITY; MULTIPLE ORGAN FAILURE; OBESITY; PANDEMIC INFLUENZA; PATIENT CARE; PHASE 3 CLINICAL TRIAL (TOPIC); POST EXPOSURE PROPHYLAXIS; PREGNANCY; PRIORITY JOURNAL; PROTECTIVE CLOTHING; RANDOMIZED CONTROLLED TRIAL (TOPIC); RAPID ANTIGEN TEST; RELIABILITY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; RHINORRHEA; RNA ANALYSIS; SEASONAL INFLUENZA; SORE THROAT; TREATMENT DURATION; TREATMENT OUTCOME; VIRAL CLEARANCE; VIRUS CULTURE; VIRUS IDENTIFICATION; VIRUS PNEUMONIA;

ANTIVIRAL AGENTS; HOSPITALIZATION; HUMANS; INFLUENZA, HUMAN; RISK FACTORS; TREATMENT OUTCOME;

EID: 84860350780     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: 10.3851/IMP2059     Document Type: Review

References (153)

1. World Health Organization. Influenza. (Accessed 31 January 2011.) Available from http://www.who.int/topics/influenza/en
2. Writing committee of the WHO consultation on Clinical Aspects of Pandemic H1N1 2009 Influenza. Clinical aspects of pandemic 2009 influenza A (H1N1) virus infection. N Engl J Med 2010; 362:1708-1719.
3. Centers for Disease Control and Prevention. Estimates of deaths associated with seasonal influenza - United States, 1976-2007. MMWR Morb and Mortal Wkly Rept 2010; 59:1057-1062.
4. Fiore AE, Fry A, Shay D, et al. Antiviral agents for the treatment and chemoprophylaxis of influenza - recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2011; 60:1-24.
5. Harper SA, Bradley JS, Englund JA, et al. Seasonal influenza in adults and children - diagnosis, treatment, chemoprophylaxis, and institutional outbreak management: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis 2009; 48:1003-1032.
6. Ison MG, de Jong MD, Gilligan KJ, et al. End points for testing influenza antiviral treatments for patients at high risk of severe and life-threatening disease. J Infect Dis 2010; 201:1654-1662.
7. Hayden FG, Palese P. Influenza virus. In Richman DD, Whitley RJ, Hayden FG (Editors). Clinical Virology. 3rd ed. Washington: ASM Press 2009; pp. 943-976.
8. Smith GJ, Vijaykrishna D, Bahl J, et al. Origins and evolutionary genomics of the 2009 swine-origin H1N1 influenza A epidemic. Nature 2009; 459:1122-1125.
9. Garten RJ, Davis CT, Russell CA, et al. Antigenic and genetic characteristics of swine-origin 2009 A(H1N1) influenza viruses circulating in humans. Science 2009; 325:197-201.
10. Wong CM, Yang L, Chan K P, et al. Influenza-associated hospitalization in a subtropical city. PLoS Med 2006; 3:e121.
11. Thompson WW, Shay DK, Weintraub E, et al. Influenzaassociated hospitalizations in the United States. JAMA 2004; 292:1333-1340.
12. Simmerman JM, Chittaganpitch M, Levy J, et al. Incidence, seasonality and mortality associated with influenza pneumonia in Thailand: 2005-2008. PLoS ONE 2009; 4:e7776.
13. Cohen C, Simonsen L, Kang J W, et al. Elevated influenzarelated excess mortality in South African elderly individuals, 1998-2005. Clin Infect Dis 2010; 51:1362-1369.
14. Hak E, Wei F, Nordin J, Mullooly J, Poblete S, Nichol KL. Development and validation of a clinical prediction rule for hospitalization due to pneumonia or influenza or death during influenza epidemics among communitydwelling elderly persons. J Infect Dis 2004; 189:450-458. (Pubitemid 38210581)
15. Dao CN, Kamimoto L, Nowell M, et al. Adult hospitalizations for laboratory-positive influenza during the 2005-2006 through 2007-2008 seasons in the United States. J Infect Dis 2010; 202:881-888.
16. Thompson WW, Shay DK, Weintraub E, et al. Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA 2003; 289:179-186. (Pubitemid 36068705)
17. Dodds L, McNeil SA, Fell DB, et al. Impact of influenza exposure on rates of hospital admissions and physician visits because of respiratory illness among pregnant women. CMAJ 2007; 176:463-468. (Pubitemid 46374354)
18. Hartert T V, Neuzil KM, Shintani AK, et al. Maternal morbidity and perinatal outcomes among pregnant women with respiratory hospitalizations during influenza season. Am J Obstet Gynecol 2003; 189:1705-1712. (Pubitemid 38056448)
19. Ison MG, Lee N. Influenza 2010-2011: lessons from the 2009 pandemic. Cleve Clin J Med 2010; 77:812-820.
20. Louie JK, Acosta M, Samuel MC, et al. A novel risk factor for a novel virus: obesity and 2009 pandemic influenza A (H1N1). Clin Infect Dis 2011; 52:301-312.
21. Morgan OW, Bramley A, Fowlkes A, et al. Morbid obesity as a risk factor for hospitalization and death due to 2009 pandemic influenza A(H1N1) disease. PLoS ONE 2010; 5:e9694.
22. Van Kerkhove MD, Vandemaele KA, Shinde V, et al. Risk factors for severe outcomes following 2009 influenza A (H1N1) Infection: a global pooled analysis. PLoS Med 2011; 8:e1001053.
23. Jain S, Kamimoto L, Bramley AM, et al. Hospitalized patients with 2009 H1N1 influenza in the United States, April-June 2009. N Engl J Med 2009; 361:1935-1944.
24. Louie JK, Acosta M, Winter K, et al. Factors associated with death or hospitalization due to pandemic 2009 influenza A(H1N1) infection in California. JAMA 2009; 302:1896-1902.
25. Domínguez-Cherit G, Lapinsky SE, Macias AE, et al. Critically Ill patients with 2009 influenza A(H1N1) in Mexico. JAMA 2009; 302:1880-1887.
26. Kumar A, Zarychanski R, Pinto R, et al. Critically ill patients with 2009 influenza A(H1N1) infection in Canada. JAMA 2009; 302:1872-1879.
27. Campbell A, Rodin R, Kropp R, et al. Risk of severe outcomes among patients admitted to hospital with pandemic (H1N1) influenza. CMAJ 2010; 182:349-355.
28. The ANZIC Influenza Investigators. Critical care services and 2009 H1N1 influenza in Australia and New Zealand. N Engl J Med 2009; 361:1925-1934.
29. Louie JK, Acosta M, Jamieson DJ, Honein MA, California Pandemic (H1N1) Working Group. Severe 2009 H1N1 influenza in pregnant and postpartum women in California. N Engl J Med 2010; 362:27-35.
30. Jamieson DJ, Honein MA, Rasmussen SA, et al. H1N1 2009 influenza virus infection during pregnancy in the USA. Lancet 2009; 374:451-458.
31. Siston AM, Rasmussen SA, Honein MA, et al. Pandemic 2009 influenza A(H1N1) virus illness among pregnant women in the United States. JAMA 2010; 303:1517-1525.
32. World Health Organization. Cumulative number of confirmed human cases of avian influenza A/(H5N1) reported to WHO. Global alert and response (GAR). (Accessed January 2011.) Available from http://www.who.int/csr/disease/avian- influenza/country/cases-table-2011-01-20/en/index.html
33. Writing Committee of the Second World Health Organization Consultation on Clinical Aspects of Human Infection with Avian Influenza A (H5N1) Virus. Update on avian influenza A (H5N1) virus infection in humans. N Engl J Med 2008; 358:261-273.
34. Adisasmito W, Chan PK, Lee N, et al. Effectiveness of antiviral treatment in human influenza A(H5N1) infections: analysis of a global patient registry. J Infect Dis 2010; 202:1154-1160.
35. Liem NT, Tung CV, Hien ND, et al. Clinical features of human influenza A (H5N1) infection in Vietnam: 2004-2006. Clin Infect Dis 2009; 48:1639-1646.
36. Kandun IN, Tresnaningsih E, Purba WH, et al. Factors associated with case fatality of human H5N1 virus infections in Indonesia: a case series. Lancet 2008; 372:744-749.
37. Lee N, Choi K W, Chan PK, et al. Outcomes of adults hospitalised with severe influenza. Thorax 2010; 65:510-515.
38. Lee N, Chan PK, Choi KW, et al. Factors associated with early hospital discharge of adult influenza patients. Antivir Ther 2007; 12:501-508. (Pubitemid 47041148)
39. McGeer A, Green KA, Plevneshi A, et al. Antiviral therapy and outcomes of influenza requiring hospitalization in Ontario, Canada. Clin Infect Dis 2007; 45:1568-1575. (Pubitemid 351411840)
40. Murata Y, Walsh EE, Falsey AR. Pulmonary complications of interpandemic influenza A in hospitalized adults. J Infect Dis 2007; 195:1029-1037. (Pubitemid 46452109)
41. Babcock HM, Merz LR, Fraser VJ. Is influenza an influenza-like illness? Clinical presentation of influenza in hospitalized patients. Infect Control Hosp Epidemiol 2006; 27:266-270.
42. Walsh EE, Cox C, Falsey AR. Clinical features of influenza A virus infection in older hospitalized persons. J Am Geriatr Soc 2002; 50:1498-1503. (Pubitemid 35024641)
43. Viasus D, Paño-Pardo JR, Pachón J, et al. Factors associated with severe disease in hospitalized adults with pandemic (H1N1) 2009 in Spain. Clin Microbiol Infect 2011; 17:738-746.
44. Denholm JT, Gordon CL, Johnson PD, et al. Hospitalised adult patients with pandemic (H1N1) 2009 influenza in Melbourne, Australia. Med J Aust 2010; 192:84-86.
45. Lee N, Chan PK, Wong CK, et al. Viral clearance and inflammatory response patterns in adults hospitalized for pandemic 2009 influenza A(H1N1) virus pneumonia. Antivir Ther 2011; 16:237-247.
46. Jennings LC, Anderson T P, Beynon KA, et al. Incidence and characteristics of viral community-acquired pneumonia in adults. Thorax 2008; 63:42-48.
47. Johnstone J, Majumdar SR, Fox JD, Marrie TJ. Viral infection in adults hospitalized with community-acquired pneumonia: prevalence, pathogens, and presentation. Chest 2008; 134:1141-1148.
48. Mandell LA, Wunderink RG, Anzueto A, et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of communityacquired pneumonia in adults. Clin Infect Dis 2007; 44 Suppl 2:S27-S72. (Pubitemid 46290553)
49. Rello J, Rodriguez A, Ibanez P, et al. Intensive care adult patients with severe respiratory failure caused by Influenza A (H1N1)v in Spain. Crit Care 2009; 13:R148.
50. Agarwal P P, Cinti S, Kazerooni EA. Chest radiographic and CT findings in novel swine-origin influenza A (H1N1) virus (S-OIV) infection. AJR Am J Roentgenol 2009; 193:1488-1493.
51. To KK, Hung I F, Li IW, et al. Delayed clearance of viral load and marked cytokine activation in severe cases of pandemic H1N1 2009 influenza virus infection. Clin Infect Dis 2010; 50:850-859.
52. Lee N, Wong CK, Chan PK, et al. Hypercytokinemia and hyperactivation of phospho-p38 mitogen-activated protein kinase in severe human influenza A virus infection. Clin Infect Dis 2007; 45:723-731. (Pubitemid 47378886)
53. Bermejo-Martin J F, Martin-Loeches I, Rello J, et al. Host adaptive immunity deficiency in severe pandemic influenza. Crit Care 2010; 14:R167.
54. Peiris JS, Cheung CY, Leung CY, Nicholls JM. Innate immune responses to influenza A H5N1: friend or foe? Trends Immunol 2009; 30:574-584.
55. Vlahos R, Stambas J, Bozinovski S, Broughton BR, Drummond GR, Selemidis S. Inhibition of Nox2 oxidase activity ameliorates influenza A virus-induced lung inflammation. PLoS Pathog 2011; 7:e1001271.
56. Wang S, Le TQ, Kurihara N, et al. Influenza viruscytokine-protease cycle in the pathogenesis of vascular hyperpermeability in severe influenza. J Infect Dis 2010; 202:991-1001.
57. Lee N, Chan PK, Lui GC, et al. Complications and outcomes of pandemic 2009 influenza A (H1N1) virus infection in hospitalized adults: how do they differ from those in seasonal influenza? J Infect Dis 2011; 203:1739-1747.
58. McCullers JA. Effect of antiviral treatment on the outcome of secondary bacterial pneumonia after influenza. J Infect Dis 2004; 190:519-526.
59. Peltola VT, Murti KG, McCullers JA. Influenza virus neuraminidase contributes to secondary bacterial pneumonia. J Infect Dis 2005; 192:249-257. (Pubitemid 40993394)
60. McAuley JL, Chipuk JE, Boyd KL, Van De Velde N, Green DR, McCullers JA. PB1-F2 proteins from H5N1 and 20 century pandemic influenza viruses cause immunopathology. PLoS Pathog 2010; 6:e1001014.
61. Lat A, Bhadelia N, Miko B, Furuya EY, Thompson GR, III. Invasive aspergillosis after pandemic (H1N1) 2009. Emerg Infect Dis 2010; 16:971-973.
62. Mallia P, Johnston SL. How viral infections cause exacerbation of airway diseases. Chest 2006; 130:1203-1210. (Pubitemid 44583754)
63. Gorse GJ, O'Connor TZ, Hall SL, Vitale JN, Nichol KL. Human coronavirus and acute respiratory illness in older adults with chronic obstructive pulmonary disease. J Infect Dis 2009; 199:847-857.
64. Lee N, Chan PK, Hui DS, et al. Viral loads and duration of viral shedding in adult patients hospitalized with influenza. J Infect Dis 2009; 200:492-500.
65. Giannella M, Alonso M, Garcia de Viedma D, et al. Prolonged viral shedding in pandemic influenza A(H1N1): clinical significance and viral load analysis in hospitalized patients. Clin Microbiol Infect 2011; 17:1160-1165.
66. Wong BC, Lee N, Li Y, et al. Possible role of aerosol transmission in a hospital outbreak of influenza. Clin Infect Dis 2010; 51:1176-1183.
67. World Health Organization. Infection prevention and control in health care for confirmed or suspected cases of pandemic (H1N1) 2009 and influenza-like illnesses. (Accessed 1 November 2010.) Available from http://www.who.int/csr/ resources/publications/swineflu/swineinfinfcont/en/index.html
68. Warren-Gash C, Smeeth L, Hayward AC. Influenza as a trigger for acute myocardial infarction or death from cardiovascular disease: a systematic review. Lancet Infect Dis 2009; 9:601-610.
69. Smeeth L, Thomas SL, Hall AJ, Hubbard R, Farrington P, Vallance P. Risk of myocardial infarction and stroke after acute infection or vaccination. N Engl J Med 2004; 351:2611-2618. (Pubitemid 39628582)
70. Emsley HC, Hopkins SJ. Acute ischaemic stroke and infection: recent and emerging concepts. Lancet Neurol 2008; 7:341-353. (Pubitemid 351380535)
71. Siriwardena AN, Gwini SM, Coupland CA. Influenza vaccination, pneumococcal vaccination and risk of acute myocardial infarction: matched case-control study. CMAJ 2010; 182:1617-1623.
72. Ciszewski A, Bilinska ZT, Brydak LB, et al. Influenza vaccination in secondary prevention from coronary ischaemic events in coronary artery disease: FLUCAD study. Eur Heart J 2008; 29:1350-1358. (Pubitemid 351806477)
73. Grau AJ, Fischer B, Barth C, Ling P, Lichy C, Buggle F. Influenza vaccination is associated with a reduced risk of stroke. Stroke 2005; 36:1501-1506. (Pubitemid 40967520)
74. Casscells SW, Granger E, Kress AM, Linton A, Madjid M, Cottrell L. Use of oseltamivir after influenza infection is associated with reduced incidence of recurrent adverse cardiovascular outcomes among military health system beneficiaries with prior cardiovascular diseases. Circ Cardiovasc Qual Outcomes. 2009; 2:108-115.
75. Madjid M, Curkendall S, Blumentals WA. The influence of oseltamivir treatment on the risk of stroke after influenza infection. Cardiology 2009; 113:98-107.
76. Lee N, Wong CK, Chan PK, et al. Acute encephalopathy associated with influenza A infection in adults. Emerg Infect Dis 2010; 16:139-142.
77. Wang GF, Li W, Li K. Acute encephalopathy and encephalitis caused by influenza virus infection. Curr Opin Neurol 2010; 23:305-311.
78. Sivadon-Tardy V, Orlikowski D, Porcher R, et al. Guillain-Barre syndrome and influenza virus infection. Clin Infect Dis 2009; 48:48-56.
79. Muller MP, McGeer AJ, Hassan K, Marshall J, Christian M, the Toronto Invasive Bacterial Disease Network. Evaluation of pneumonia severity and acute physiology scores to predict ICU admission and mortality in patients hospitalized for influenza. PLoS ONE 2010; 5:e9563.
80. Nichols WG, Guthrie KA, Corey L, Boeckh M. Influenza infections after hematopoietic stem cell transplantation: risk factors, mortality, and the effect of antiviral therapy. Clin Infect Dis 2004; 39:1300-1306. (Pubitemid 39458515)
81. Chemaly R F, Torres HA, Aguilera EA, et al. Neuraminidase inhibitors improve outcome of patients with leukemia and influenza: an observational study. Clin Infect Dis 2007; 44:964-967. (Pubitemid 46452062)
82. Nguyen-Van-Tam JS, Openshaw PJ, Hashim A, et al. Risk factors for hospitalisation and poor outcome with pandemic A/H1N1 influenza: United Kingdom first wave (May-September 2009). Thorax 2010; 65:645-651.
83. Santa-Olalla Peralta P, Cortes-García M, Vicente-Herrero M, et al. Risk factors for disease severity among hospitalised patients with 2009 pandemic influenza A (H1N1) in Spain, April-December 2009. Euro Surveill 2010; 15:19667.
84. Estenssoro E, Ríos FG, Apezteguía C, et al. Pandemic 2009 influenza A in Argentina: a study of 337 patients on mechanical ventilation. Am J Respir Crit Care Med 2010; 182:41-48.
85. Skarbinski J, Jain S, Bramley A, et al. Hospitalized patients with 2009 pandemic influenza A (H1N1) virus infection in the United States - September-October 2009. Clin Infect Dis 2011; 52 Suppl 1:S50-S59.
86. Xi X, Xu Y, Jiang L, Li A, Duan J, Du B, the Chinese Critical Care Clinical Trial Group. Hospitalized adult patients with 2009 influenza A(H1N1) in Beijing, China: risk factors for hospital mortality. BMC Infect Dis 2010; 10:256.
87. van den Dool C, Hak E, Wallinga J, van Loon AM, Lammers JW, Bonten MJ. Symptoms of influenza virus infection in hospitalized patients. Infect Control Hosp Epidemiol 2008; 29:314-319. (Pubitemid 351416981)
88. McGeer AJ. Diagnostic testing or empirical therapy for patients hospitalized with suspected influenza: what to do? Clin Infect Dis 2009; 48 Suppl 1:S14-S19.
89. Falsey AR, Murata Y, Walsh EE. Impact of rapid diagnosis on management of adults hospitalized with influenza. Arch Intern Med 2007; 167:354-360. (Pubitemid 46333935)
90. Hassan K, McGeer A, Green KA, et al. Antiviral therapy improves outcome of influenza infections in patients requiring admission to intensive care. 49th Interscience Conference on Antimicrobial Agents and Chemotherapy. 12-15 September 2009, San Francisco, CA, USA. Abstract V-537.
91. D'Heilly SJ, Janoff EN, Nichol P, Nichol KL. Rapid diagnosis of influenza infection in older adults: influence on clinical care in a routine clinical setting. J Clin Virol 2008; 42:124-128.
92. Yeh E, Luo RF, Dyner L, et al. Preferential lower respiratory tract infection in swine-origin 2009 A(H1N1) influenza. Clin Infect Dis 2010; 50:391-394.
93. Petric M, Comanor L, Petti CA. Role of the laboratory in diagnosis of influenza during seasonal epidemics and potential pandemics. J Infect Dis 2006; 194 Suppl 2:S98-S110. (Pubitemid 44630953)
94. Ison MG, Rosenberg ES. RNA respiratory viruses. In Hayden RT, Carroll KC, Tang YW, Wolk DM (Editors). Diagnostic microbiology of the immunocompromised host. Washington: ASM Press 2009; pp. 141-160.
95. Ngai KLK, Lam WY, Lee N, Leung TF, Hui DSC, Chan PKS. Allele-specific conventional reverse-transcription polymerase chain reaction as a screening assay for discriminating influenza A H1N1 (H275Y) oseltamivir-resistant and wide-type viruses. J Med Virol 2010; 82:1295-1298.
96. Hayden F. Developing new antiviral agents for influenza treatment: what does the future hold? Clin Infect Dis 2009; 48 Suppl 1:S3-S13.
97. Ariano RE, Sitar DS, Zelenitsky SA, et al. Enteric absorption and pharmacokinetics of oseltamivir in critically ill patients with pandemic (H1N1) influenza. CMAJ 2010; 182:357-363.
98. Taylor WR, Thinh BN, Anh GT, et al. Oseltamivir is adequately absorbed following nasogastric administration to adult patients with severe H5N1 influenza. PLoS ONE 2008; 3:e3410.
99. Schünemann HJ, Hill SR, Kakad M, et al. WHO rapid advice guidelines for pharmacological management of sporadic human infection with avian influenza A (H5N1) virus. Lancet Infect Dis 2007; 7:21-31. (Pubitemid 44932137)
100. Medeiros R, Rameix-Welti MA, Lorin V, et al. Failure of zanamivir therapy for pneumonia in a bone-marrow transplant recipient infected by a zanamivir-sensitive influenza A (H1N1) virus. Antivir Ther 2007; 12:571-576. (Pubitemid 47041157)
101. Kiatboonsri S, Kiatboonsri C, Theerawit P. Fatal respiratory events caused by zanamivir nebulization. Clin Infect Dis 2010; 50:620.
102. Tanaka T, Nakajima K, Murashima A, Garcia-Bournissen F, Koren G, Ito S. Safety of neuraminidase inhibitors against novel influenza A (H1N1) in pregnant and breastfeeding women. CMAJ 2009; 181:55-58.
103. Donner B, Niranjan V, Hoffmann G. Safety of oseltamivir in pregnancy: a review of preclinical and clinical data. Drug Saf 2010; 33:631-642.
104. Ison MG, Gnann JW, Jr., Nagy-Agren S, et al. Safety and efficacy of nebulized zanamivir in hospitalized patients with serious influenza. Antivir Ther 2003; 8:183-190. (Pubitemid 36960891)
105. Ison MG, Mcgeer AJ, Hui DS, et al. Safety and efficacy of multiple-day treatment with intravenous peramivir or oral oseltamivir in hospitalized adults with acute influenza. XI International Symposium on Respiratory Viral Infections. 19-22 February 2009, Bangkok, Thailand.
106. Yates PJ, Man CY, Zhao H, et al. Interim virlogical analysis of a propsective single arm Phase II study of intravenous zanamivir for the treatment of hospitalized patients with influenza A/H1N1 2009 infection. Options for the Control of Influenza VII. 3-7 September 2010, Hong Kong, SAR, China. Abstract P-160.
107. South East Asia Infectious Disease Clinical Research Network (SEAIDCRN) SEA001 Protocol Team. SEA001: High-dose vs Standard-dose oseltamivir for the treatment of severe influenza. Options for the Control of Influenza VII. 3-7 September 2010, Hong Kong, SAR, China. Abstract P-205.
108. Hanshaoworakul W, Simmerman JM, Narueponjirakul U, et al. Severe human influenza infections in Thailand: oseltamivir treatment and risk factors for fatal outcome. PLoS ONE 2009; 4:e6051.
109. Khanna N, Steffen I, Studt JD, et al. Outcome of influenza infections in outpatients after allogeneic hematopoietic stem cell transplantation. Transpl Infect Dis 2009; 11:100-105.
110. Kumar D, Michaels MG, Morris MI, et al. Outcomes from pandemic influenza A H1N1 infection in recipients of solid-organ transplants: a multicentre cohort study. Lancet Infect Dis 2010; 10:521-526.
111. Baccam P, Beauchemin C, Macken CA, Hayden FG, Perelson AS. Kinetics of influenza A virus infection in humans. J Virol 2006; 80:7590-7599. (Pubitemid 44092580)
112. Aoki FY, Macleod MD, Paggiaro P, et al. Early administration of oral oseltamivir increases the benefits of influenza treatment. J Antimicrob Chemother 2003; 51:123-129. (Pubitemid 36163836)
113. Leekha S, Zitterkopf NL, Espy MJ, Smith TF, Thompson RL, Sampathkumar P. Duration of influenza A virus shedding in hospitalized patients and implications for infection control. Infect Control Hosp Epidemiol 2007; 28:1071-1076. (Pubitemid 47345268)
114. Ling LM, Chow AL, Lye DC, et al. Effects of early oseltamivir therapy on viral shedding in 2009 pandemic influenza A (H1N1) virus infection. Clin Infect Dis 2010; 50:963-969.
115. Wattanagoon Y, Stepniewska K, Lindegårdh N, et al. Pharmacokinetics of high-dose oseltamivir in healthy volunteers. Antimicrob Agents Chemother 2009; 53:945-952
116. Kobayashi S, Kimura F, Kobayashi A, Sato K, Motoyoshi K. Influenza virus reactivation after remission with oseltamivir treatment in a patient undergoing nonmyeloablative bone marrow transplantation. J Infect Chemother 2008; 14:308-310.
117. Ison MG. Anti-influenza therapy: the emerging challenge of resistance. Therapy 2009; 6:883-891.
118. Birnkrant D, Cox E. The Emergency use authorization of peramivir for treatment of 2009 H1N1 influenza. N Engl J Med 2009; 361:2204-2207.
119. Campbell AP, Jacob ST, Kuypers J, et al. Respiratory failure caused by 2009 novel influenza A/H1N1 in a hematopoietic stem-cell transplant recipient: Detection of extrapulmonary H1N1 RNA and use of intravenous peramivir. Ann Intern Med 2010; 152:619-620.
120. Hernandez JE, Adiga R, Armstrong R, et al. Clinical experience in adults and children treated with intravenou peramivir for 2009 influenza A (H1N1) under an Emergency IND program in the United States. Clin Infect Dis 2011; 52:695-706.
121. Kohno S, Kida H, Mizuguchi M, Shimada J. Efficacy and safety of intravenous peramivir for treatment of seasonal influenza virus infection. Antimicrob Agents Chemother 2010; 54:4568-4574.
122. Shigeru Kohno, Hiroshi Kida, Masashi Mizuguchi, et al. Intravenous peramivir for treatment of influenza A and B virus infection in high-risk patients. Antimicrob Agents Chemother 2011; 55:2803-2812.
123. Gaur AH, Bagga B, Barman S, et al. Intravenous zanamiv for oseltamivir-resistant 2009 H1N1 influenza. N Engl J Med 2010; 362:88-89.
124. Kidd IM, Down J, Nastouli E, et al. H1N1 pneumonitis treated with intravenous zanamivir. Lancet 2009; 374:1036.
125. Dulek DE, Williams J V, Creech CB, et al. Use of intravenous zanamivir after development of oseltamivir resistance in a critically ill immunosuppressed child infected with 2009 pandemic influenza A (H1N1) virus. Clin Infect Dis 2010; 50:1493-1496.
126. Busani S, Girardis M, Biagioni E, Pasetto A, Sambri V. Surfactant therapy and intravenous zanamivir in severe respiratory failure due to persistent influenza A/H1N1 2009 virus infection. Am J Respir Crit Care Med 2010; 182:1334.
127. Härter G, Zimmermann O, Maier L, et al. Intravenous zanamivir for patients with pneumonitis due to pandemic (H1N1) 2009 influenza virus. Clin Infect Dis 2010; 50:1249-1251.
128. Hayden FG, de Jong MD. Emerging influenza antiviral resistance threats. J Infect Dis 2011; 203:6-10.
129. Gooskens J, Jonges M, Claas EC, Meijer A, van den Broek PJ, Kroes AM. Morbidity and mortality associated with nosocomial transmission of oseltamivirresistant influenza A(H1N1) virus. JAMA 2009; 301:1042-1046.
130. Dharan NJ, Gubareva LV, Meyer JJ, et al. Infections with oseltamivir-resistant influenza A(H1N1) virus in the United States. JAMA 2009; 301:1034-1041.
131. Lackenby A, Thompson CI, Democratis J. The potential impact of neuraminidase inhibitor resistant influenza. Curr Opin Infect Dis 2008; 21:626-638.
132. de Jong MD, Tran TT, Truong HK, et al. Oseltamivir resistance during treatment of influenza A (H5N1) infection. N Engl J Med 2005; 353:2667-2672. (Pubitemid 41817715)
133. Gooskens J, Jonges M, Claas EC, Meijer A, Kroes AC. Prolonged influenza virus infection during lymphocytopenia and frequent detection of drug-resistant viruses. J Infect Dis 2009; 199:1435-1441.
134. Baz M, Abed Y, Papenburg J, Bouhy X, Hamelin ME, Boivin G. Emergence of oseltamivir-resistant pandemic H1N1 virus during prophylaxis. N Engl J Med 2009; 361:2296-2297.
135. Tramontana AR, George B, Hurt AC, et al. Oseltamivir resistance in adult oncology and hematology patients infected with pandemic (H1N1) 2009 virus, Australia. Emerg Infect Dis 2010; 16:1068-1075.
136. Moore C, Galiano M, Lackenby A, et al. Evidence of person-to-person transmission of oseltamivir-resistant pandemic influenza A(H1N1) 2009 virus in a hematology unit. J Infect Dis 2011; 203:18-24.
137. Memoli MJ, Hrabal RJ, Hassantoufighi A, Eichelberger MC, Taubenberger JK. Rapid selection of oseltamivir- and peramivir-resistant pandemic H1N1 virus during therapy in 2 immunocompromised hosts. Clin Infect Dis 2010; 50:1252-1255.
138. Renaud C, Pergam SA, Polyak C, et al. Early emergence of an H275Y mutation in a hematopoietic cell transplant recipient treated with intravenous peramivir. Transpl Infect Dis 2010; 12:513-517.
139. van der Vries E, Stelma F F, Boucher CA. Emergence of a multidrug-resistant pandemic influenza A (H1N1) virus. N Engl J Med 2010; 363:1381-1382.
140. Nguyen JT, Hoopes JD, Le MH, et al. Triple combination of amantadine, ribavirin, and oseltamivir is highly active and synergistic against drug resistant influenza virus strains in vitro. PLoS ONE 2010; 5:e9332.
141. Smee DF, Hurst BL, Wong MH, Bailey KW, Morrey JD. Effects of double combinations of amantadine, oseltamivir, and ribavirin on influenza A (H5N1) virus infections in cell culture and in mice. Antimicrob Agents Chemother 2009; 53:2120-2128.
142. Duval X, van der Werf S, Blanchon T, et al. Efficacy of oseltamivir-zanamivir combination compared to each monotherapy for seasonal influenza: a randomized placebo-controlled trial. PLoS Med 2010; 7:e1000362.
143. Salgado CD, Farr BM, Hall KK, Hayden FG. Influenza in the acute hospital setting. Lancet Infect Dis 2002; 2:145-155. (Pubitemid 34462449)
144. Voirin N, Barret B, Metzger MH, Vanhems P. Hospitalacquired influenza: a synthesis using the Outbreak Reports and Intervention Studies of Nosocomial Infection (ORION) statement. J Hosp Infect 2009; 71:1-14.
145. Grayson ML, Melvani S, Druce J, et al. Efficacy of soap and water and alcohol-based hand-rub preparations against live H1N1 influenza virus on the hands of human volunteers. Clin Infect Dis 2009; 48:285-291.
146. Siegel JD, Rhinehart E, Jackson M, Chiarello L, the Healthcare Infection Control Practices Advisory Committee. 2007 guidelines for isolation precautions: preventing transmission of infectious agents in healthcare settings. 2009. (Accessed September 2010.) Available from http://www.cdc.gov/hicpac/pdf/ isolation/Isolation2007.pdf
147. Cowling BJ, Chan KH, Fang VJ, et al. Facemasks and hand hygiene to prevent influenza transmission in households: a cluster randomized trial. Ann Intern Med 2009; 151:437-446.
148. Loeb M, Dafoe N, Mahony J, et al. Surgical mask vs N95 respirator for preventing influenza among health care workers: a randomized trial. JAMA 2009; 302:1865-1871.
149. Tellier R. Transmission of influenza A in human beings. Lancet Infect Dis 2007; 7:759-760, author reply 61-63. (Pubitemid 350152036)
150. Hui DS, Chow BK, Ng SS, et al. Exhaled air dispersion distances during noninvasive ventilation via different Respironics face masks. Chest 2009; 136:998-1005.
151. Malato L, Llavador V, Marmier E, Youssef J, Balick Weber C, Rozé H, Bessede E, Fleury HJ. Pandemic influenza A(H1N1) 2009: molecular characterisation and duration of viral shedding in intensive care patients in Bordeaux, south-west France, May 2009 to January 2010. Euro Surveill 2011; 16:19776.
152. Wise ME, De Perio M, Halpin J, et al. Transmission of pandemic (H1N1) 2009 influenza to healthcare personnel in the United States. Clin Infect Dis 2011; 52 Suppl 1:S198-S204.
153. Chor JS, Ngai KL, Goggins WB, et al. Willingness of Hong Kong healthcare workers to accept pre-pandemic influenza vaccination at different WHO alert levels: two questionnaire surveys. BMJ 2009; 339:b3391